Estimating attrition in mild-to-moderate Alzheimer's disease and mild cognitive impairment clinical trials.

ABSTRACT:

Background

Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer's disease (AD) is an area of active treatment development. We aimed to quantify the association between trial duration and completion rates and provide guidance for estimating attrition in AD trial protocols.

Methods

Using the Alzforum and ClinicalTrials.gov databases, we analyzed retention data from 125 mild-to-moderate AD and 12 mild cognitive impairment (MCI) clinical trials. We compared the rates of completion between trial arms (active vs. control) and ran regression models to test the hypothesis that trials with longer study duration have lower trial completion using all available data and restri

SUBMITTER: Ritchie M 

PROVIDER: S-EPMC10662394 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature